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The Fourth Universal Definition of Myocardial Infarction (MI) differentiates MI from myocar-
dial injury. We characterised the temporal course of cardiac and non-cardiac outcomes
associated with MI, acute and chronic myocardial injury.
Methods
We included all patients presenting to public emergency departments in South Australia
between June 2011–Sept 2019. Episodes of care (EOCs) were classified into 5 groups
based on high-sensitivity troponin-T (hs-cTnT) and diagnostic codes: 1) Acute MI [rise/fall in
hs-cTnT and primary diagnosis of acute coronary syndrome], 2) Acute myocardial injury
with coronary artery disease (CAD) [rise/fall in hs-cTnT and diagnosis of CAD], 3) Acute
myocardial injury without CAD [rise/fall in hs-cTnT without diagnosis of CAD], 4) Chronic
myocardial injury [elevated hs-cTnT without rise/fall], and 5) No myocardial injury. Multivari-
able flexible parametric models were used to characterize the temporal hazard of death, MI,
heart failure (HF), and ventricular arrhythmia.
Results
372,310 EOCs (218,878 individuals) were included: acute MI (19,052 [5.12%]), acute myo-
cardial injury with CAD (6,928 [1.86%]), acute myocardial injury without CAD (32,231
[8.66%]), chronic myocardial injury (55,056 [14.79%]), and no myocardial injury (259,043
[69.58%]). We observed an early hazard of MI and HF after acute MI and acute myocardial
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injury with CAD. In contrast, subsequent MI risk was lower and more constant in patients
with acute injury without CAD or chronic injury. All patterns of myocardial injury were associ-
ated with significantly higher risk of all-cause mortality and ventricular arrhythmia.
Conclusions
Different patterns of myocardial injury were associated with divergent profiles of subsequent
cardiac and non-cardiac risk. The therapeutic approach and modifiability of such excess
risks require further research.
Introduction
Cardiac troponin is a highly sensitive biomarker for myocardial injury that plays an essential
role in the diagnosis and risk-stratification of acute myocardial infarction (MI) [1, 2]. The
improved analytical sensitivity of the new high-sensitivity cardiac troponin (hs-cTn) assays
facilitates early diagnosis of MI. However, these assays come with new challenges including
increased identification of troponin elevations above the conventional reference threshold
(>99th percentile upper reference limit) in patients without objective evidence of myocardial
ischemia (e.g. on echocardiography or ECG) [3–5].
The Fourth Universal Definition of MI is the first guideline to formally define this syn-
drome as myocardial injury and distinguish it from MI. It outlines three main patterns of tro-
ponin elevation—acute MI, acute myocardial injury and chronic myocardial injury [2]. Acute
MI is defined as myocardial injury with clinical evidence of myocardial ischaemia and can be
subdivided into five types: type 1 (atherosclerotic plaque rupture), type 2 (supply-demand mis-
match), type 3 (cardiac death prior to availability of troponin results), type 4 (percutaneous
coronary intervention related), and type 5 (cardiac surgery related) [2]. In contrast, myocardial
injury is defined as an elevated troponin without evidence of myocardial ischaemia, and is sub-
divided into acute and chronic injury depending on the presence or absence of an observed
rise and/or fall in troponin levels, respectively [2].
A number of studies have indicated that myocardial injury is now the most common cause
of troponin elevation [4, 6, 7] and confers a poor prognosis independent of the underlying
mechanism of its elevation [6, 8–11]. There is also evolving evidence to suggest that each of
these different patterns of troponin elevation has distinct clinical consequences [12, 13]. For
example, patients with acute myocardial injury and type 2 MI appear to have worse short-term
[14] and long-term [12, 13] mortality compared with patients with type 1 MI [7, 13, 15–18].
However, the temporal association with subsequent cardiovascular complications, such as MI
and heart failure (HF), are uncertain. Another critical difference between the diagnoses of
myocardial injury and MI is the disparity in evidence to inform clinical management. While
there is rich evidence to guide the management of type 1 MI, there is little evidence to guide
the management of patients with type 2 MI and myocardial injury [19–21]. This is especially
pertinent as type 1 MI accounts for a relatively small proportion of all detectable troponin ele-
vations and myocardial injury is increasingly observed in clinical practice [4, 6, 10].
The short- and long-term consequences of different classifications and patterns of troponin
elevation may provide crucial insights into the design of future clinical trials to test interven-
tions to treat myocardial injury without MI. The aim of the present study was to characterise
the temporal hazard of cardiac and non-cardiac events associated with the different classifica-
tions and patterns of troponin elevation using population-level data from a large health system
in Australia.
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Methods
Study population and diagnostic classifications
We identified consecutive patients presenting to public hospital emergency departments (EDs)
in South Australia between July 2011 to September 2019 who had at least one high-sensitivity
cardiac troponin-T (hs-cTnT) measured during their ED stay. In July 2011, a 5th generation hs-
cTnT assay was implemented across all public hospitals in the state by a single pathology service,
with the same assay implemented at all facilities. Troponin results were linked to hospital rec-
ords and International Classification of Diseases primary and secondary diagnostic codes, ver-
sion 10 Australian Modified (ICD-10 AM). Each encounter was considered as a new episode of
care (EOC). Each EOC for a given patient was linked longitudinally allowing representation to
hospital to serve both as an outcome for the prior EOC as well as a new EOC. Transfers between
hospitals were considered as part of the same EOC. All diagnostic codes for patients transferred
between hospitals were evaluated to ensure all suitable cases were identified. Episodes of care
were excluded from the analyses if troponin testing was not performed or if there was only a sin-
gle borderline elevated hs-cTnT (29-52ng/L) since a troponin pattern could not be determined
from these episodes of care based on published studies [22–25]. Patients admitted through ED
for elective coronary artery bypass surgery were also excluded due the expected differences in
subsequent prognosis. Each EOC was followed up for a minimum of 12 months and was cen-
sored at the time of last known follow-up. The decision for all clinical management was made at
the treating physician’s discretion, independent of this study.
Trained independent coding professionals, applying standardized audited protocols, used
medical record documentation, imaging and pathology data to classify primary and secondary
diagnoses for each clinical presentation. Within the current coding conventions, the diagnoses
listed as the “primary diagnosis” were deemed to be the main reason for which the patient pre-
sented for clinical attention. “Secondary diagnoses” represent those conditions recognized to
impact the complexity of subsequent clinical care. Where more than one cardiac diagnostic
code was present, the primary diagnostic code was used. Significant past medical conditions
were determined by examining hospitalization records from the preceding 10 years. Deaths
and their cause were identified through hospital records and the State Death Registry.
The study population was identified based on the above inclusion and exclusion criteria
and was not anonymized during the data linkage process, although the final dataset was fully
anonymized. As part of the de-identification process, a unique identifier was created and
assigned to each patient by the data manager to allow for identification of reattendances. The
unique identifier obviates the risk of re-identification and was only accessible by the data man-
ager. After a unique identifier was assigned to each participant, the dataset was then fully de-
identified for analysis purposes. The need for patient consent was waived by the local ethics
committee as there were robust procedures to ensure sufficient protection of patient data as
per Australian National Statement guidelines (Section 2.3.6), the study involved negligible risk
to the study participants and there is adequate plan to ensure the ongoing confidentiality of
the data. The Human Research Ethics Committee of the South Australian Department of
Health and Wellbeing provided approval to access all datasets described above and this study
complies with the Declaration of Helsinki (HREC/19/SAH/36).
Biomarker measurements
The indication and timing for hs-cTnT testing was clinically determined. All troponin samples
were analysed using 5th generation hs-cTnT assay (Roche Diagnostics: lower limit of quantifi-
cation: 5ng/L; 99th percentile upper reference limit in a normal population: male =�22ng/L,
PLOS ONE Troponin elevation pattern and subsequent cardiac and non-cardiac outcomes
PLOS ONE | https://doi.org/10.1371/journal.pone.0248289 March 12, 2021 3 / 17
female =�14ng/L; lowest concentration with a coefficient of variation <10%: 4.49 ng/L). Dur-
ing the study period, an elevated troponin was only reported to the treating clinician at a hs-
cTnT concentration�29ng/L due to previous and ongoing studies [26, 27]. A clinically signifi-
cant rise and/or fall was determined as a relative change of�20% or a gradient of�3ng/L/hr
from initial to any subsequent measurement within 24 hours as per expert consensus and
existing literature [2, 28].
Group definitions
We classified each EOC into five groups based on their troponin pattern and primary/second-
ary discharge diagnoses to maximally align with the Fourth Universal Definition of MI. Epi-
sodes of care rather than individual patient-level analysis was chosen as pattern
characterisation of hs-cTnT allows for dynamic risk assessment which is expected to vary in an
individual over time. Additional sensitivity analysis was also performed excluding patients
with very high frequency of non-cardiovascular hospital presentations (�4 ED presentations
per year unrelated to the outcomes of interest).
1) Acute MI. Defined as an EOC with at least one elevated hs-cTnT measurement above
99th centile (male:�22ng/L, female:�14ng/L) with a qualifying rise and/or fall (relative
change of�20% or gradient of�3ng/L/hr within the first 24 hours of presentation) and a pri-
mary diagnostic code of coronary artery disease (CAD) (ICD-10-AM codes I20-I25). In addi-
tion, EOC were also classified as acute MI if the following criteria were fulfilled: a) patients
who died within 12 hours of presentation with at least one elevated hs-cTnT and had a primary
diagnosis of MI (ICD-10-AM of I21), b) patients who had a single hs-cTnT�52ng/L and with
a primary diagnosis of MI (ICD-10-AM of I21) if only one hs-cTnT measurement was per-
formed, and c) patients who had a hs-cTnT >250ng/L without an observed rise and/or fall
with a primary diagnosis of MI (ICD-10-AM of I21). The hs-cTnT cut-off value of� 52ng/L
was chosen based on published studies [22–25].
2) Acute myocardial injury with recognized CAD. Defined as an EOC with at least one
elevated hs-cTnT measurement with a qualifying rise and/or fall and a secondary diagnostic
code associated with CAD (ICD-10-AM codes I20-I25), but where the primary diagnostic
code was not due to an acute coronary syndrome. This classification implied an underlying
supply-demand ischaemia mechanism as an approximation of Type 2 MI but does not always
exclude a diagnosis of acute type 1 MI.
3) Acute myocardial injury without recognized CAD. Defined as an EOC with at least
one elevated hs-cTnT measurement with a qualifying rise and/or fall without any diagnostic
codes associated with CAD or previously known CAD diagnosis.
4) Chronic myocardial injury. Defined as an EOC with at least one elevated hs-cTnT
measurement without a qualifying rise and/or fall.
5) No myocardial injury. Defined as an EOC with no hs-cTnT above 99th centile.
To mitigate against misclassification bias associated with using administrative data, 6,362
EOC were adjudicated by two independent clinicians and the classification criteria were opti-
mised using the adjudicated diagnoses. The final optimised classification criteria had an accu-
racy of 85.35% (S2 Table). The majority of the misclassification was due to borderline hs-cTnT
results, borderline hs-cTnT changes (e.g. female patient with hs-cTnT level of 13.9 ng/L, rela-
tive hs-cTnT change of 19%), and the presence of uncoded CAD.
Outcomes of interest
The primary outcomes assessed were times to all-cause mortality, new/recurrent acute MI and
associated complications (I21-I23), HF admissions (I42, I43, I255, I50, J81) and the composite
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outcome of ventricular arrhythmias and cardiac arrest (I46, I47.0, I47.2, I47.9). Acute MI was
chosen as it infers an underlying coronary atherosclerosis as a substrate of subsequent risk,
which may be modified by coronary-specific investigations and therapies (e.g. HMG-CoA
reductase inhibitors, antiplatelet agents and anatomical assessment +/- coronary revascularisa-
tion). HF admission and ventricular arrhythmia/cardiac arrest were chosen as they may repre-
sent medium to long-term consequences of myocardial damage. Time to admission for
pneumonia and neck of femur fracture (NOFF) were chosen as secondary outcomes of interest
as these non-cardiac clinical events may provide insights into systemic burden of co-morbidity
and frailty, respectively.
Statistical analysis
Continuous variables were tested for normal distribution and were reported either as means
with standard deviation or as medians with 25th and 75th percentiles. Categorical variables
were reported as frequencies and proportions. Baseline characteristics were compared using
Pearson’s chi-square test for categorical variables and analysis of variance or Kruskal-Wallis
test for continuous variables where appropriate.
To estimate the excess hazard associated with different types of MI and myocardial injury,
multivariable flexible parametric models with time-varying covariates and restricted cubic splines
(varying spline knots) with utilized and EOC with no myocardial injury as the comparator [29,
30]. The selection of the number of internal spline knots in the Royston and Parmar (RP) model
was guided by optimizing the Akaike information criterion. The proportional hazards scale was
used in the RP model to facilitate comparison of the hazard ratios (HRs) observed. Estimates are
reported as HRs with 95% confidence intervals (95% CI). Factors considered as potential con-
founders were age in years, sex, lowest in-hospital estimated glomerular filtration rate (eGFR),
maximal in-hospital hs-cTnT, clinical comorbidities such as diabetes mellitus, chronic obstructive
pulmonary disease, dementia, peripheral artery disease, and previous stroke. A sensitivity analysis
was performed excluding patients with very high frequency of non-cardiovascular hospital pre-
sentations (�4 ED presentations per year unrelated to the outcomes of interest).
In a secondary analysis, the consequence of repeated injury associated with each type of
myocardial injury was assessed by including a cumulative count variable of the different myo-
cardial injury types in Cox regression models (e.g. 1, 2, or� 3 prior presentations with chronic
myocardial injury). The model used for this analysis corrected for previous MI or myocardial
injury types, as a patient may experience more than one type of myocardial injury during the
follow-up period (e.g. 2 prior presentation of chronic myocardial injury and 1 prior presenta-
tion of acute myocardial injury), and other clinical covariates included in the flexible paramet-
ric models. The measured outcomes from this analysis were the HRs of subsequent acute MI
and HF admissions. For this analysis, acute MI and acute myocardial injury with recognized
CAD were merged and treated as one group as they both have CAD as a substrate of subse-
quent ischaemic risk. All reported p-values were 2-sided, and statistical significance was set at
p<0.05. All analyses were performed using STATA 16.1 (College Station TX, USA).
Results
Patient characteristics
Cohort selection is outlined in Fig 1. Between June 2011 and September 2019, 372,310 EOC
(218,878 individual patients) out of a total of 1,595,725 EOC (246,381 individual patients) met
the inclusion criteria and were included in the analysis (Fig 1). Episodes of care were classified
into five groups based on the a priori defined criteria: 1) Acute MI (n = 19,052, 5.12%), 2)
Acute myocardial injury with recognized CAD (n = 6,928, 1.86%), 3) Acute myocardial injury
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without recognized CAD (n = 32,231, 8.66%), 4) Chronic myocardial injury (n = 55,056,
14.79%), and 5) No myocardial injury (n = 259,043, 69.58%). The clinical characteristics of
patients in each group are presented in Table 1. Overall, acute MI accounted for 16.8% of all
EOCs with hs-cTnT elevation and this group had the highest level of peak hs-cTnT. Patients
who had chronic myocardial injury were older, had lowest peak hs-cTnT levels, and greater
burden of co-morbidities. Compared with patients who had acute myocardial injury with
CAD, patients who had acute myocardial injury without recognized CAD were of comparable
age but had lower peak hs-cTnT levels.
Short- and long-term outcomes
The observed incidence of all-cause mortality, subsequent MI, HF admission, and ventricular
arrhythmias or cardiac arrest at 1-month, and 1-year are presented in Table 2. The unadjusted
Fig 1. Study flow diagram. CAD = Coronary artery disease. CABG = coronary artery bypass graft.
https://doi.org/10.1371/journal.pone.0248289.g001
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1-year mortality following EOCs with acute myocardial injury with CAD was higher than
those with acute MI (acute MI: 533/19052 [2.80%], acute injury with CAD: 325/6928 [4.69%],
acute injury without CAD: 945/32231 [2.93%]; overall p-value: <0.001). The risk for subse-
quent MI was highest following acute MI, although the risk following acute myocardial injury
with recognized CAD was also high. The observed 1-year incidence of pneumonia and NOFF
were similar across all groups (S1 Table). Using the flexible multivariable parametric models,
the adjusted temporal HRs for all-cause mortality, subsequent MI, HF admission and ventricu-
lar arrhythmias or cardiac arrest for the four groups were modelled (Fig 2, Table 3, S1 Fig).
Distinct patterns of risk were observed for each group. Among patients with acute MI, we
observed an early hazard for recurrent MI that slowly declined over time. In contrast, patients
with acute myocardial injury with recognized CAD had a more constantly elevated hazard of
future MI whilst patients without recognized CAD (either acute or chronic injury pattern) had
a lower risk of future MI (adjusted 1-year HR of MI in acute myocardial injury with CAD
group: HR = 2.6, 95% confidence interval [95%CI] = 2.25–3.04; acute myocardial injury with-
out CAD group: HR = 1.51, 95%CI = 1.33–1.72; chronic myocardial injury group: HR = 1.95,











injury (n = 55,056)
No myocardial
injury (n = 259,043)
P-value
Age (years, median, i.q.
rb)
70 (58–81) 78 (68–86) 77 (66–90) 81 (72–87) 56 (43–69) <0.001
Female (n, %) 6,231 (32.71) 2,853 (41.18) 15,867 (49.23) 24,811 (45.07) 130,428 (50.36) <0.001
1-year all-cause
mortality (n, %)
533 (2.80) 325 (4.69) 945 (2.93) 772 (1.40) 481 (0.19) <0.001
1-year myocardial
infarction (n, %)
244 (1.28) 28 (0.4) 87 (0.27) 151 (0.27) 127 (0.05) <0.001
Maximum 24-hour hs-
cTnTc (ng/L, median, i.
q.r)
338 (100–1159) 212 (70–524) 50 (28–114) 39 (25–63) 6 (3–9) <0.001
eGFRd (mLs/min/
1.73m2, median, i.q.r)
71 (52–88) 53 (34–73) 61 (41–82) 54 (36–74) 90 (76–106) <0.001
Known diabetes mellitus
(n, %)
4,524 (23.75) 2,415 (34.86) 8,909 (27.64) 19,492 (35.40) 30,130 (11.63) <0.001
Known COPDe (n, %) 1,497 (7.86) 1,255 (18.11) 5,456 (16.93) 10,805 (19.63) 13,852 (5.35) <0.001
Known PADf (n, %) 1,371 (7.20) 836 (12.07) 2,794 (8.67) 6,289 (11.42) 6,089 (2.35) <0.001
Prior CVAg (n, %) 850 (4.46) 543 (7.84) 2,232 (6.93) 4,687 (8.51) 6,913 (2.67) <0.001
Known dementia (n, %) 455 (2.39) 342 (4.94) 1,587 (4.92) 3,488 (6.34) 2,552 (0.99) <0.001
Known prior heart
failure
2278 (11.96) 1999 (28.85) 7156 (22.20) 16622 (30.19) 12234 (4.72) <0.001
Known prior ventricular
arrhythmia




12469 (64.45) 1787 (25.79) 1295 (4.02) 2467 (4.48) 5696 (2.20)
aCAD = coronary artery disease
bi.q.r. = interquartile range,
chs-cTnT = high-sensitivity troponin-T
deGFR = estimated glomerular filtration rate
eCOPD = chronic obstruction pulmonary disease
fPAD = peripheral artery disease
gCVA = cerebral vascular disease.
https://doi.org/10.1371/journal.pone.0248289.t001
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95% = 1.79–2.13). We also observed that all patterns of myocardial injury were associated with
an early risk of all-cause mortality with acute injury (with or without CAD) at the greatest
risks. Both acute MI and acute myocardial injury with recognised CAD were associated with
an early hazard of HF, whereas the other two groups had a more constantly elevated hazard of
subsequent HF. All groups were associated with excess risk of ventricular arrhythmias or car-
diac arrest, with acute myocardial injury with recognized CAD at the highest risk (Fig 2, S1
Fig). Excluding multiple repeat non-cardiovascular presentations (�4 ED presentations per
year unrelated to the outcomes of interest) did not significant change the overall pattern of
results (S3 Table).
Effect of recurrent injury types
To assess the consequences of repeated myocardial injury or infarction, a ‘cumulative injury
count’ variable was included in Cox regression models with the type of injury subdivided into
three groups: 1) acute myocardial injury with CAD (pooled acute MI and acute myocardial
injury with recognized CAD), 2) acute myocardial injury without recognized CAD and 3)
chronic myocardial injury (Fig 3, S4 Table).
Based on the flexible multivariable model, a strong dose-response relationship was observed
between the number of episodes of acute myocardial injury with recognized CAD and subse-
quent MI risk. In contrast, the association between cumulative episodes of acute myocardial
injury without recognized CAD or chronic myocardial injury and the subsequent risk of MI
were not as pronounced (Fig 3A, S4 Table). All three groups were associated with an incre-
mental increase in risk of subsequent HF admission (Fig 3B, S4 Table).
Discussion
The Fourth Universal Definition of MI attempts to simplify the complexities in the interpreta-
tion and management of different patterns of cardiac troponin elevation by defining three dis-
tinct phenotypic patterns (acute MI, acute myocardial injury and chronic myocardial injury)
Table 2. Observed incidence of all-cause mortality, subsequent myocardial infarction, heart failure admission and ventricular arrhythmia or cardiac arrest at
1-month, and 1-year.
All-cause mortality Subsequent MI HF admission Ventricular arrhythmia/ cardiac arrest
Acute myocardial infarction (n = 19,052)
1-month (n, %) 178 (0.93) 4 (0.02) 1 (0.01) 0 (0)
1-year (n, %) 533 (2.80) 244 (1.28) 103 (0.54) 4 (0.02)
Acute myocardial injury with recognized CAD (n = 6,928)
1-month (n, %) 71 (1.02) 0 (0) 0 (0) 0 (0)
1-year (n, %) 325 (4.69) 28 (0.40) 51 (0.74) 5 (0.07)
Acute myocardial injury without recognized CAD (n = 32,231)
1-month (n, %) 262 (0.81) 10 (0.03) 4 (0.01) 0 (0)
1-year (n, %) 945 (2.93) 87 (0.27) 163 (0.51) 11 (0.03)
Chronic myocardial injury (n = 55,056)
1-month (n, %) 99 (0.18) 6 (0.01) 10 (0.02) 1 (<0.01)
1-year (n, %) 772 (1.40) 151 (0.27) 419 (0.76) 18 (0.03)
No myocardial injury (n = 259,043)
1-month (n, %) 137 (0.05) 8 (<0.01) 8 (<0.01) 1 (<0.01)
1-year (n, %) 481 (0.19) 127 (0.05) 172 (0.07) 32 (0.01)
CAD = coronary artery disease, MI = myocardial infarction, HF = heart failure.
https://doi.org/10.1371/journal.pone.0248289.t002
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[2]. While there exists a robust evidence-base to guide management and risk stratification of
acute MI, especially for type 1 acute MI (atherosclerotic plaque disruption), there is a lack of
guiding evidence for prognosis-modifying therapies for patients with acute and chronic myo-
cardial injury [20, 21]. In this population-level cohort study, we characterized the temporal
risk associated with different troponin elevation patterns and subtypes and examined the clini-
cal outcomes after repeated presentations of myocardial injury or infarction. The primary
findings of this study were: 1) the divergent profiles of subsequent risk amongst the different
phenotypes of myocardial injury, 2) additive risk for subsequent MI in repeat presentations of
acute myocardial injury with recognized CAD, 3) the value of troponin as a cardiac-selective
risk stratification tool in patients with high burden of competing non-cardiac comorbidities,
and 4) the high proportion of non-MI hs-cTnT elevations. To our knowledge, this is the first
health system-level study to evaluate the individual temporal clinical consequences associated
with different phenotypes of myocardial injury using a contemporary high-sensitivity troponin
assay. Our study should inform the design of future clinical trials of current and emerging
therapies that may impact cardiac outcomes among these high-risk groups currently not
served by an evidence base to guide therapy.
Our observation of distinct temporal profiles of subsequent clinical events may provide
insights into potential underlying pathophysiology for each phenotype of troponin elevation
Fig 2. Estimated hazard ratio of A) all-cause mortality, B) subsequent myocardial infarction, C) subsequent heart failure admission
and D) ventricular arrhythmia or cardiac arrest in patients with acute myocardial infarction, acute myocardial injury with recognized
coronary artery disease, acute myocardial injury without recognized coronary artery disease and chronic myocardial injury, relative to
patients with no myocardial injury. Graphs were adjusted for age in years, sex, lowest in-hospital estimated glomerular filtration rate,
maximal in-hospital high-sensitivity troponin-T, clinical comorbidities including diabetes mellitus, chronic obstructive pulmonary
disease, dementia, peripheral artery disease, and previous stroke. MI = myocardial infarction. CAD = coronary artery disease.
https://doi.org/10.1371/journal.pone.0248289.g002
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assessed (Fig 2, S1 Fig). The acute MI group showed an expected pattern consistent with acute
plaque rupture, with an early elevated risk for mortality, MI, heart failure and ventricular
arrhythmias, which diminishes over time. Therapies with the likely greatest risk-modifying
potential for this group are therefore acute coronary-specific therapies in keeping with current
guidelines (i.e. antiplatelet therapies, early non-invasive or invasive anatomical assessment +/-
revascularisation, and HMG-CoA reductase inhibitors) [19–21]. In contrast to acute MI, the
myocardial injury groups did not show the pattern of early elevated ischaemic risk. Instead,
the elevated ischaemic risk was only seen in patients with documented CAD and was more
constant over time (Fig 2, S1 Fig). Prior studies that have characterised outcomes following
non-type 1 MI have been limited by relatively small sample sizes or have combined clinical
endpoints such as recurrent MI and heart failure, thus making it difficult to propose putative
mechanisms for poor long-term outcomes [7, 13, 16]. Consistent with these studies [7, 13, 16],
we observed a higher risk of long-term all-cause mortality in myocardial injury than in MI. It
remains unclear whether this higher mortality in myocardial injury is due to fundamental dif-
ferences in the mechanism(s) of troponin elevation, the influence of comorbidities, or the
effect of disease-specific treatment available. Our observation that patients with acute myocar-
dial injury without recognized CAD had higher all-cause mortality despite having lower subse-
quent ischaemic risk suggests that these patients may not benefit from therapies targeted at
acute plaque rupture and may in fact be harmed by them due to the concomitant bleeding
risk. This may be especially relevant during the Coronavirus-19 pandemic where acute myo-
cardial injury is common and bleeding risk is high [31–34]. Overall, we observed a lower
1-year mortality in the chronic myocardial injury group compared to other studies [7, 12, 16],
although after adjustment, the mortality risk of this group was comparable to the acute MI
group (adjusted 1-year hazard ratio of mortality for chronic injury vs. acute MI: 2.53 vs. 2.25).
Table 3. Adjusted hazard ratios of 30-day, 1-year and 3-year all-cause mortality, recurrent myocardial infarction, subsequent heart failure admission, and ventricu-
lar arrhythmias or cardiac arrest in the acute myocardial infarction, acute myocardial injury with recognized coronary artery disease, acute myocardial injury with-
out recognized coronary artery disease and chronic myocardial injury groups based on flexible parametric models.
All-cause mortality Recurrent MI HF admission Ventricular arrhythmia/ cardiac arrest
Acute myocardial infarction
30-day HR (95%CI) 2.98 (2.04–4.33) 9.04 (7.96–10.28) 2.61 (2.26–3.00) 2.63 (2.03–3.42)
1-year HR (95%CI) 2.25 (1.95–2.60) 5.87 (5.38–6.41) 1.15 (1.03–1.27) 1.48 (1.21–1.82)
3-year HR (95% CI) 1.87 (1.76–2.00) 4.84 (34.3–5.42) 0.90 (0.79–1.02) 1.30 (1.09–1.53)
Acute myocardial injury with recognized CAD
30-day HR (95%CI) 7.58 (5.19–11.07) 3.34 (2.59–4.31) 2.74 (2.30–3.27) 3.65 (2.62–5.12)
1-year HR (95%CI) 3.80 (3.28–4.40) 2.61 (2.25–3.04) 1.44 (1.30–1.60) 2.37 (1.90–2.95)
3-year HR (95%CI) 3.04 (2.75–3.36) 2.00 (1.61–2.49) 1.16 (1.02–1.33) 1.93 (1.54–2.48)
Acute myocardial injury without recognized CAD
30-day HR (95%CI) 5.86 (4.29–8.00) 2.21 (1.80–22.71) 2.14 (1.89–2.42) 2.67 (2.08–3.42)
1-year HR (95%CI) 3.14 (2.80–3.51) 1.51 (1.33–1.72) 1.44 (1.33–1.56) 1.74 (1.45–2.09)
3-year HR (95%CI) 2.29 (2.16–2.43) 1.44 (1.24–1.67) 1.20 (1.11–1.31) 1.35 (1.12–1.68)
Chronic myocardial injury
30-day HR (95%CI) 4.27 (3.32–5.49) 2.36 (2.02–2.745 2.27 (2.05–2.52) 1.88 (1.49–2.35)
1-year HR (95%CI) 2.53 (2.30–2.79) 1.95 (1.79–2.13) 1.66 (1.57–1.75) 1.52 (1.32–1.76)
3-year HR (95%CI) 2.03 (1.92–2.15) 1.70 (1.51–1.92) 1.46 (1.37–1.56) 1.45 (1.32–1.66)
Flexible parametric model adjusted for age in years, sex, lowest in-hospital estimated glomerular filtration rate, maximal in-hospital high-sensitivity troponin-T, clinical
comorbidities including diabetes mellitus, chronic obstructive pulmonary disease, dementia, peripheral artery disease, and previous stroke. CAD = coronary artery
disease, HR = hazard ratio, 95%CI = 95% confidence interval, MI = myocardial infarction, HF = heart failure.
https://doi.org/10.1371/journal.pone.0248289.t003
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The relatively low unadjusted mortality may be partially explained by the fact that our analysis
focused on characterization of patients’ risk “per encounter” and patients who were initially
classified as chronic myocardial injury may subsequently experience an ‘acute injurious’ event
that preceded mortality and therefore the mortality risk was attributed to acute injury. Lastly,
we found no association between myocardial injury (both acute and chronic) and markers
of frailty (subsequent NOFF) or susceptibility to illness (subsequent pneumonia) after cor-
recting for potential confounders. Whilst previous studies have suggested that troponin
elevation may be non-specific in patients with highly competing non-cardiac comorbidities
[35–37], our findings suggest that troponin remains a useful tool for cardiac-selective risk
stratification.
One of the key findings of this study was the observation of the large potentially modifiable
risk for recurrent MI in patients with acute myocardial injury with recognized CAD, com-
pared to the other two injury groups (acute myocardial injury without recognized CAD and
chronic myocardial injury). In this study, we chose to additionally subdivide acute myocardial
injury into patients with and without recognized CAD, under the hypothesis that these repre-
sent distinct mechanistic subgroups. In keeping with this hypothesis, we observed clear differ-
ences between these two subgroups especially in the risk of subsequent MI (Fig 2, Table 3, S1
Fig). Specifically, we observed a greater than 3-fold increase in risk of subsequent MI in
patients with acute myocardial injury with recognized CAD that was not observed in those
without recognized CAD. The difference between the early elevated risk in acute MI and the
constantly elevated MI risk in acute myocardial injury likely represent a mechanistic difference
in acute plaque rupture versus more stable coronary artery disease (Fig 2, S1 Fig). We also
observed an incremental dose-response relationship between repeated acute myocardial injury
with recognized CAD and subsequent ischaemic events (Fig 3). This dose-response relation-
ship was not detected in patients with acute myocardial injury without recognized CAD or
chronic myocardial injury, further supporting the concept of distinct underlying pathophysiol-
ogies between phenotypes. A previous study has also observed a difference between these sub-
groups, as CAD was shown to be an independent risk factor for major adverse cardiovascular
events in patients with myocardial injury or type 2 MI [13]. Thus, our results would suggest
the potential benefit of invasive or non-invasive anatomical assessment in patients with acute
myocardial injury if coronary anatomy is unknown, followed by coronary-specific preventa-
tive therapies such as HMG-CoA reductase inhibitors to mitigate their risk for subsequent cor-
onary events. This, of course, requires clinical judgement in the balancing of the risks
associated with vascular access (if invasive) and contrast-induced kidney injury. Overall, whilst
previous studies have demonstrated an association between troponin elevation and poor out-
come [7, 13, 15–18], our findings suggest that each pattern of troponin elevation likely necessi-
tate distinct risk-modifying strategies to mitigate these outcomes. These concepts of coronary
investigation and directed therapies require further prospective evaluation in randomized clin-
ical trials, two of which are ongoing–The Appropriateness of Coronary investigation in myo-
cardial injury and Type 2 myocardial infarction (ACT-2; ACTRN12618000378224) [26] trial
Fig 3. Estimated hazard ratio of A) subsequent myocardial infarction(s) and B) subsequent heart failure admission(s)
in patients with 1, 2, and�3 recurrent episodes of acute myocardial injury with recognized coronary artery disease
(combined group 1 and 2), acute myocardial injury without recognized coronary artery disease (group 3) and chronic
myocardial injury (group 4). Graphs were adjusted for adjusted for age in years, sex, lowest in-hospital estimated
glomerular filtration rate, maximal in-hospital high-sensitivity troponin-T, clinical comorbidities including diabetes
mellitus, chronic obstructive pulmonary disease, dementia, peripheral artery disease, and previous stroke. model.
CAD = coronary artery disease, HF = heart failure, MI = myocardial infarction. � denotes statistically significant trend
with p-value<0.05.
https://doi.org/10.1371/journal.pone.0248289.g003
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and the DEtermining the Mechanism of myocardial injury AND role of coronary disease in
type 2 Myocardial Infarction (DEMAND MI; NCT03338504) trials.
Several limitations of this study should be considered. First, misclassification between
patients with acute myocardial injury, chronic myocardial injury and acute MI is possible
given the reliance of this study on the application of national coding rules, which may differ
from clinical impression. However, this was mitigated with manual adjudication of over 6,000
EOCs and optimization of the classification criteria. Furthermore, consistency of diagnostic
classification is known to be clinically very challenging especially in the setting of borderline
hs-cTnT results and co-existent illnesses. In using standardized coding data and a trend
towards under-diagnosis of CAD following adjudication, misclassification of encounters is
likely non-differential, resulting in an underestimation of the effect estimates whilst preserving
the direction of effect. Second, while we adjusted our models for key prognostic variables,
residual unrecognized confounding and the impact of down-stream treatments may impact
the magnitude of the observed excess hazard for various events. In part, exploring the associa-
tion between troponin patterns and subsequent presentations with pneumonia and fractured
neck of femur attempts to provide an evaluation of unmeasured confounding, and the lack of
significant association with these recurrent events is reassuring. Lastly, we chose to use EOC-
based rather than individual-level analysis allowing risk to vary dynamically with time, which
may lead to correlated outcomes among frequent presenters. However, the impact of this bias
is mitigated by the large available sample, the small proportion attributable to multiple
repeated episodes within the same patient, and sensitivity analysis.
In conclusion, we have characterized the temporal pattern of excess hazard and potential
mechanisms associated with the different phenotypes of myocardial necrosis using definitions
guided by the Fourth Universal Definition of MI and high-sensitivity troponin. We observed
distinct patterns of temporal risk in each group suggesting distinct therapies may be required
to modify clinical outcomes. In particular, we observed a significant and additive risk for sub-
sequent MI in patients with acute myocardial injury with CAD, suggesting potential benefit of
early anatomical assessment and coronary-directed therapies. Further randomised and obser-
vational studies are required to further assess the potential role of coronary- and myocardial-
targeted therapies in these populations.
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S1 Fig. Estimated hazard ratio of all-cause mortality, subsequent myocardial infarction, heart
failure admission and ventricular arrhythmia or cardiac arrest in patients with A) acute myo-
cardial infarction, B) acute myocardial injury with recognized coronary artery disease, C)
acute myocardial injury without recognized coronary artery disease and D) chronic myocar-
dial injury, relative to patients with no myocardial injury. Graphs were adjusted for age in
years, sex, lowest in-hospital estimated glomerular filtration rate, maximal in-hospital high-
sensitivity troponin-T, clinical comorbidities including diabetes mellitus, chronic obstructive
pulmonary disease, dementia, peripheral artery disease, and previous stroke.
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S2 Fig. Estimated hazard ratio of pneumonia (left) and neck of femur fracture (right) in
patients with acute myocardial infarction, acute myocardial injury with recognized coronary
artery disease, acute myocardial injury without recognized coronary artery disease and chronic
myocardial injury, relative to patients with no myocardial injury. Graphs were adjusted for all
variables included in the flexible parametric model.
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maximal in-hospital high-sensitivity troponin-T, clinical comorbidities such as diabetes melli-
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mal in-hospital high-sensitivity troponin-T, clinical comorbidities including diabetes mellitus,
chronic obstructive pulmonary disease, dementia, peripheral artery disease, and previous stroke.
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